Associate Professor Christopher Chen
Yong Loo Lin School of Medicine, National University of Singapore
Access the teams link to view the seminar HERE
“The promise and challenges of blood biomarkers for cognitive impairment and dementia”
The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct has facilitated the development of biomarker-guided, pathway-based targeted therapies, which have been approved by regulatory agencies and hence have the potential to enter global clinical practice.
These advances herald an unprecedented paradigm shift and require an new global framework for clinical care pathways for AD. In this talk I shall describe how we may transition from the current, clinical symptom-focused and inherently late-stage diagnosis and management of AD to the next-generation pathway that incorporates biomarker-guided decision-making algorithms for risk stratification, early detection, timely diagnosis, and preventative or therapeutic interventions.
I shall address critical high-priority challenges and propose strategic solutions such as blood biomarkers for cognitive impairment and dementia.
